Key Takeaways
- Deep brain stimulation (DBS) is adjustable, implanted therapy for selected symptoms; it is not a cure and does not stop neurodegeneration.[1]
- Candidacy is diagnosis-specific. Parkinson disease, essential tremor, dystonia and epilepsy require different clinical evidence, targets and outcome measures.
- For Parkinson disease, useful levodopa response, disabling motor fluctuations, dyskinesia or selected refractory tremor often matter. Dementia, uncontrolled psychiatric illness, atypical parkinsonism and symptoms unlikely to respond can change the balance.[1][2]
- The operation does not finish when the leads and pulse generator are implanted. Programming, medication adjustment, wound review and rehabilitation are part of the treatment.
- Target, side, lead model, battery type and programming platform must be documented. They affect expected benefit, adverse effects, MRI conditions and where follow-up can occur.
- An international patient should identify a compatible programming centre at home before surgery, not after the first setting problem or depleted battery.
Content
DBS is often described as a “brain pacemaker,” but the comparison is incomplete. The system usually includes one or more leads in selected brain targets, extensions under the skin and an implantable pulse generator in the chest or abdomen. Electrical settings can be changed, yet the biological disease, lead location and patient's function still set limits.[1]
A good DBS consultation begins with a symptom inventory and a long-term service plan. A technically successful implant can still disappoint when the wrong symptom was targeted or when no one near the patient's home can programme the device.
Name the diagnosis before discussing a target
DBS is used for several conditions, but one label does not create one pathway.
- Parkinson disease: the aim is usually to reduce medication-responsive rigidity, slowness, tremor, “off” time or troublesome dyskinesia. DBS does not reliably correct every gait, speech, swallowing or cognitive problem and does not stop disease progression.[1][2]
- Essential tremor: the important outcome is functional—drinking, writing, eating, dressing or working—not only a lower tremor score. First confirm the tremor syndrome and adequate non-surgical treatment.
- Dystonia: pattern, cause, distribution, fixed deformity, pain and prior medication or botulinum toxin matter. Response may emerge gradually rather than immediately.
- Epilepsy: DBS is a network-modulation option for selected drug-resistant epilepsy, not the same as removing a safely localised seizure focus.[1]
- Other indications: regulatory status and evidence can differ by country and device. “DBS is approved” is incomplete without the condition, system and jurisdiction.
NICE recommends multidisciplinary selection for Parkinson disease and for tremor or dystonia.[3][4] The team should include clinicians who can diagnose the disorder, implant the system, programme it, assess cognition and mood, and manage rehabilitation.
Convert symptoms into measurable treatment goals
“Walk better” or “shake less” is too vague for consent. Record two or three priorities in observable terms: minutes of disabling off time, ability to drink from a cup, painful dystonic postures, falls, time to dress or frequency of disabling seizures.
For Parkinson disease, keep a medication and symptom diary and compare a defined practically “off” examination with an “on” examination after dopaminergic medication. A useful levodopa response often predicts which motor features may respond to DBS, although medication-resistant tremor can be an exception.[1] The assessment should separate:
- bradykinesia and rigidity;
- rest, action and postural tremor;
- dyskinesia and motor fluctuations;
- freezing and balance in on and off states;
- speech and swallowing;
- cognition, hallucinations, impulse-control problems and mood; and
- pain, sleep, autonomic symptoms and caregiver burden.
NICE advises against DBS when Parkinson symptoms are adequately controlled by best medical therapy and recommends considering it in advanced disease not adequately controlled despite best medical therapy.[2] Medication infusion and other advanced options should be compared rather than presented as failures that must precede surgery.
Identify reasons to pause, optimise or choose another strategy
Age alone is not a universal cut-off. Frailty, cognition, psychiatric stability, falls, medical risk, diagnosis and expected years of device care are more informative.
The team should investigate:
- dementia or a pattern of cognitive decline that may worsen independence;
- untreated depression, psychosis, suicidality or unstable impulse-control disorder;
- atypical or secondary parkinsonism;
- severe axial, speech or swallowing symptoms that remain poor even in the best medication state;
- uncontrolled hypertension, active infection, coagulation problems or inability to safely manage antithrombotic treatment;
- poor skin integrity or previous implanted-device infection;
- inability to attend programming or operate/recharge the chosen system; and
- goals that depend on symptoms unlikely to respond.
NINDS notes that people with signs of dementia are poor DBS candidates and that most people continue some medication after surgery.[1] A “no for now” decision should say what can be optimised and when candidacy will be reviewed.
Choose the target by trade-off, not fashion
Targets vary with diagnosis and symptom profile. In Parkinson disease, the subthalamic nucleus (STN) and globus pallidus internus (GPi) are common; tremor pathways may be treated through thalamic or related targets; dystonia often uses pallidal targets; epilepsy uses a different network target. The name of a target alone is not a quality mark.
Ask the conference to explain:
- why this target suits the diagnosis and priority symptoms;
- one side or both, and whether stages are planned;
- how cognition, mood, speech, gait and medication-reduction goals influence choice;
- which alternative target was considered;
- what improvement would count as success; and
- what adverse effect would prompt reprogramming or revision.
The patient should receive a written target and laterality before consent. Marketing terms such as adaptive, directional or sensing DBS describe technical capabilities; they do not override selection and lead placement.
Understand the operation as a chain of accuracy and safety checks
DBS surgery may be awake, asleep under general anaesthesia or use both approaches. A stereotactic frame, bone-mounted platform or robotic guidance may be used. Imaging plans a trajectory that avoids vessels and reaches the intended target. Some centres record neural signals or perform test stimulation; practice varies by target and technique.
The pulse generator may be implanted the same day or in a second stage. Ask for the plan for:
- preoperative MRI/CT and image fusion;
- antibiotics and infection prevention;
- anticoagulant and antiplatelet management;
- awake versus asleep steps and how symptoms will be tested;
- confirmation of final lead position;
- management of haemorrhage, seizure, confusion or new deficit;
- generator pocket and extension routing; and
- immediate postoperative imaging and neurological observations.
Important risks include intracranial bleeding or stroke, infection, seizure, lead misplacement, cerebrospinal-fluid leak, confusion, mood or cognitive change, gait or speech deterioration, stimulation adverse effects and later hardware fracture, migration, skin erosion or battery failure.[1][4] Individual risk depends on health, technique and system.
Treat initial programming as rehabilitation, not a switch-on ceremony
The device is often programmed after early postoperative recovery. Temporary improvement from the surgical “microlesion” effect can fade, so the first good day is not the final setting.
Programming changes contact selection, current or voltage, pulse width, frequency and sometimes directional configuration. Clinicians balance symptom benefit against tingling, pulling, double vision, speech change, imbalance, dyskinesia or mood effects. Finding a stable programme can take repeated visits over weeks or months.[1]
Bring the same functional measures to each visit. Record:
- active programme and exact parameters;
- medication state during testing;
- benefits by symptom and time of day;
- stimulation-linked adverse effects;
- battery level or recharge performance; and
- the next change and how long to test it.
Medication should be changed deliberately, not stopped abruptly because stimulation has begun. Physiotherapy, occupational therapy and speech or swallowing care may still be needed; DBS can make practice more possible but does not teach movement.
Know the hardware responsibilities for life
Non-rechargeable generators need replacement when depleted; rechargeable devices require a routine the patient can perform reliably. Battery longevity depends on system and energy use, so a universal replacement interval is misleading.
The patient should carry an implant card and keep a digital copy containing manufacturer, full model names, lead and extension identifiers, serial information, implant location, implant date and treating contacts. Keep the patient programmer and charger available during travel, with suitable power adapters and instructions.
New symptoms can come from disease, medication, programming or hardware. Sudden loss of benefit, unexpected shocks, inability to communicate with the device, charging failure, redness, drainage, swelling or skin thinning along the system requires prompt contact. Fever with wound change or a new neurological deficit needs urgent assessment.
Never guess about MRI or other energy-based procedures
“DBS-compatible MRI” is not a general permission. MRI eligibility depends on the complete implanted system, lead configuration, abandoned components, anatomical scan region, scanner strength, coils, specific absorption limits, device settings and monitoring. FDA advises that an implant of unknown status be treated as MR Unsafe; MR Conditional means safe only when the labelled conditions are met.[5]
Before any MRI, the radiology team must identify the exact system and use its current manufacturer conditions. Carry the implant card and obtain an eligibility sheet or device report. CT is generally possible when clinically needed, but the radiology and DBS teams should know about the neurostimulator and follow relevant precautions.[6]
Diathermy and some electrical, magnetic, radiation or surgical procedures can damage a system or heat tissue. Dental and medical teams should be told about the implant before treatment. Do not rely on “turn it off” as a universal safety solution.
Build cross-border follow-up before choosing a device
Programming platforms and clinical support are not automatically interchangeable across manufacturers or countries. Before surgery in China, obtain written confirmation from a home centre that it can programme the exact proposed model and manage its complications. Clarify who pays for programming, remote advice, spare accessories, battery replacement and surgical revision.
CDC recommends arranging follow-up before medical travel and obtaining complete English records.[7] The discharge package should include:
- diagnosis, baseline scores and recorded goals;
- multidisciplinary candidacy conclusion and alternatives considered;
- target, side, trajectories and postoperative lead-localisation images;
- operative report and any complications;
- manufacturer and exact models for leads, extensions, generator and programmer;
- MRI-conditionality documentation for the complete configuration;
- initial and current settings plus programming history;
- generic medication list and planned adjustments;
- wound, activity, air-travel and emergency instructions; and
- dates for programming, battery checks and neurological review.
The practical question is not only “Can this centre implant DBS?” It is “Can this patient live safely with this exact system for years?”
Medical disclaimer: This article provides general education. It cannot diagnose a movement disorder or epilepsy, select a DBS target or device, assess surgical risk, programme stimulation or determine MRI safety. New weakness, severe headache, seizure, confusion, fever with wound change or other acute deterioration needs urgent local assessment.
FAQ
Does DBS cure Parkinson disease?
No. DBS can improve selected motor symptoms and fluctuations, but it does not stop the underlying neurodegenerative process.[1] Speech, balance, cognition and other symptoms may respond differently or continue to progress.
Is levodopa response required before Parkinson DBS?
A clear medication response often helps predict benefit for slowness and rigidity, while some medication-resistant tremor can still respond. The team should perform a structured on/off assessment and confirm the diagnosis rather than apply one percentage cut-off blindly.
Can DBS settings be completed before an international patient goes home?
Usually only an initial programme can be established. Swelling and microlesion effects change, medications are adjusted and different settings require real-life testing. Several programming visits over weeks or months are common.[1]
Can every person with DBS have an MRI?
No. Only an MR Safe or MR Conditional complete system may enter MRI under its exact labelled conditions; an unidentified or unverified implant should be treated as MR Unsafe.[5] The radiology and DBS teams must check the model and configuration.
What records matter most after DBS abroad?
Keep the target and side, lead-location images, operative report, full component models and identifiers, implant card, MRI conditions, current and previous settings, battery information, medication plan and compatible home programming contact.
Sources
- US National Institute of Neurological Disorders and Stroke — Deep Brain Stimulation
- National Institute for Health and Care Excellence — Parkinson's Disease in Adults (NG71)
- National Institute for Health and Care Excellence — Deep Brain Stimulation for Parkinson's Disease
- National Institute for Health and Care Excellence — Deep Brain Stimulation for Tremor and Dystonia
- US Food and Drug Administration — MRI Benefits and Risks for Patients With Implants
- US Food and Drug Administration — Preventing Damage to Neurostimulators During CT Scans
- US Centers for Disease Control and Prevention — Medical Tourism, Yellow Book 2026
Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Editorial note: The image includes a recognisable intracranial lead, extension and chest pulse-generator diagram alongside multidisciplinary counselling. It supports candidacy and device-planning content without showing a brand, a surgical claim or a guaranteed response.